Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9612 posts found.

Eyenovia announces FDA approval of first ophthalmic spray for mydriasis

May 10, 2023 Research and Development Eyenovia, FDA, Opthalmology, mydriasis, ophthalmology

Ophthalmic technology company Eyenovia has announced that the US Food and Drug Administration (FDA) has approved Mydcombi (tropicamide and phenylephrine …
News

Boehringer Ingelheim and Ginkgo Bioworks collaborate over $406m undruggable targets deal

May 9, 2023 Research and Development Boehringer Ingelheim, Rare Diseases, cell programming, ginkgo bioworks, undruggable targets

German pharmaceutical company Boehringer Ingelheim (BI) and cell programming and biosecurity platform builder Ginkgo Bioworks have announced a partnership to …
News
robina-weermeijer-so1l3jsdd3y-unsplash_2

Eli Lilly shares positive results from phase 3 study of donanemab for early Alzheimer’s disease

May 5, 2023 Research and Development Alzheimer's disease, Eli Lilly, Neurology, clinical trial, new drug

Eli Lilly has announced positive results from the TRAILBLAZER-ALZ 2 phase 3 trial assessing donanemab’s ability to slow cognitive and …
News

Vicore announces initiation of proof-of-concept study for endothelial dysfunction treatments

May 4, 2023 Research and Development Cardiology, Vicore Pharma, clinical trials, endothelial dysfunction, organ damage

Vicore Pharma Holding AB has announced that it has dosed the first patient with C21 in its randomised, double-blind, placebo-controlled, …
News

Eli Lilly shares positive analysis from phase 3 trial for lebrikizumab for atopic dermatitis

May 3, 2023 Research and Development Dermatology, Eli Lilly, Jenny Murase, atopic dermatitis, dermatology, lebrikizumab

Eli Lilly has announced new secondary analysis from its phase 3 clinical development programme for patients with atopic dermatitis (AD) …
News
cdc-d5nff1slguy-unsplash

FDA approves Pfizer’s pneumococcal conjugate vaccine for infants and children

April 28, 2023 Market Access, Research and Development, Sales and Marketing Ear Nose & throat, FDA, Immunology, Pfizer, Vaccine, pneumococcal vaccine

Pfizer has announced that the US Food and Drug Administration (FDA) has approved its PREVNAR 20 (20-valent pneumococcal conjugate vaccine) …
News
james-yarema-5tymgag0wro-unsplash_1

Daewoong Pharmaceutical and Vitalli Bio enter Global License Agreement for autoimmune disease candidate

April 28, 2023 Research and Development

South Korean Daewoong Pharmaceutical and US biotechnology company Vitalli Bio – a portfolio company of Aditum Bio – have announced …
News
huha-inc-ofvesgqrbjc-unsplash

Eli Lilly’s tirzepatide achieves 15.7% weight loss in adult patients

April 28, 2023 Research and Development

Eli Lilly has announced that tirzepatide (10mg and 15mg) achieved significant and superior weight loss compared to a placebo over …
News

First Patient Dosed in the US in Avacta’s AVA6000 Phase 1 Clinical Study

April 27, 2023 Research and Development Avacta

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs and powerful diagnostics, announces that the …
News
Press release
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

National Institutes of Health awards grant for gammaCore clinical trial for patients with opioid use disorders

April 27, 2023 Research and Development

Bioelectronic medicine and wellness company electroCore have announced that the National Institute on Drug Abuse (NIDA) part of the National …
News
testalize-me-0je8ynv4mis-unsplash

3B Pharmaceuticals and Novartis enter into licensing agreement for FAP-targeting technology

April 25, 2023 Research and Development

German biotechnology company 3B Pharmaceuticals (3BP) and Switzerland-based Novartis have announced that they have entered into a Global Exclusive Licensing …
News
towfiqu-barbhuiya-hn2hqoalbck-unsplash_1

AbbVie shares results from phase 3 trial for atogepant migraine treatment

April 24, 2023 Research and Development

AbbVie has shared positive results from its phase 3 ELEVATE study, which assessed atogepant for the preventative treatment of episodic …
News
yunus-tug-lnfgdbcajxu-unsplash

Gamida Cell’s Omisirge receives FDA approval

April 18, 2023 Research and Development

Cell therapy pioneer Gamida Cell has announced FDA approval of its allogeneic cell therapy, Omisirge (omidubicel-onlv), for use in adult …
News
towfiqu-barbhuiya-ssz6x-gao0c-unsplash

GSK announces positive data from phase 3 trial for new UTI antibiotic

April 17, 2023 Research and Development

GSK has shared positive data from its phase 3 trial for gepotidacin as a new oral antibiotic for the treatment …
News
towfiqu-barbhuiya-msqb97guxy0-unsplash

Diabeloop announces collaboration with Novo Nordisk for connected diabetes treatment

April 14, 2023 Research and Development

Automated insulin delivery company Diabeloop has announced its collaboration with global healthcare company Novo Nordisk, with an agreement which covers …
News
The Gateway to Local Adoption Series

Latest content

Kayentis and RWS partner to improve clinical trial data confidence

April 17, 2026

MHRA expands its pioneering AI Airlock programme with £3.6m funding boost

April 16, 2026

Ardena opens new US bioanalytical laboratory

April 15, 2026

Gesynta Pharma doses first patient in endometriosis phase 2 trial

April 14, 2026

Astellas Pharma’s new non-hormonal menopausal hot flush treatment Veoza can be used in the NHS, NICE says

April 13, 2026